Andrea Smadja - C19 Tamar News
After conducting an experiment on 12 patients severely affected by the virus, 11 of them recovered within four days and were able to return to their homes.
Dr. Shadi Hamoud, principal investigator of the Phase 1 trial at Rambam in Haifa, says: “The results are very dramatic. Patients who were on the verge of death have recovered, and have been sent home.”
The company’s trials have shown that treatment with the MesenCure drug has the ability to reduce inflammatory processes and improve lung function. Initial findings at Rambam Hospital showed in a clinical trial, that 16 corona patients, hospitalized in severe condition, after receiving the drug; 15 were sent home after 3 to 8 days. The only one died.
Now, the Ministry of Health has decided to purchase 500 treatments at a cost of 4 million dollars and has authorized the company to continue with phase 2 of its clinical trials in hospitals throughout the country.https://clinicaltrials.gov/ct2/show/NCT04716998
About Bonus BioGroup
Since its establishment, Bonus BioGroup has worked to develop cell therapies and tissue-engineered products for bone regeneration. The main component of the viable bone graft developed by the Company are mesenchymal stromal cells isolated from the patient’s adipose tissue. During the outbreak of the COVID-19 pandemic, the Company started to study these mesenchymal cells and their potential applications to attenuating the associated hyper-inflammatory response (i.e., cytokine storm) provoked by COVID-19 and other diseases. In the development of MesenCure, Bonus BioGroup applied a variety of unique technologies and proprietary knowledge, some of which are currently in development by the Company, and some of which are part of the Company’s broad intellectual property portfolio, which includes fourteen approved patents and eighteen patent applications in many countries around the globe.
how much you want to bet my blood and dna has alot to do with that cure